Dual‐Targeted Therapy in Cardiometabolic Risk: A Meta‐Analysis of Telmisartan‐Based Combinations for Hypertension and Dyslipidemia
Open Access
- 26 November 2025
- journal article
- research article
- Published by Wiley in Clinical Cardiology
- Vol. 48 (12) , e70211
Abstract
Background: Hypertension often coexists with dyslipidemia, requiring combination therapy. Telmisartan, combined with amlodipine or rosuvastatin, targets these conditions. This meta‐analysis evaluates the efficacy and safety of these combinations in adults with hypertension and dyslipidemia. Methods: A systematic search was conducted in Cochrane Central, MEDLINE/PubMed, ClinicalTrials.gov, and ScienceDirect (as of June 2024) for randomized controlled trials (RCTs) comparing telmisartan plus amlodipine versus telmisartan plus rosuvastatin in adults (≥ 18 years) with hypertension and dyslipidemia. A random‐effects model was used with RevMan 5.4.1. The risk of bias and heterogeneity were assessed with the Cochrane Risk of Bias Tool and the I ² statistic. Results: Three RCTs involving 320 participants were included. At 4 weeks, telmisartan + amlodipine yielded greater sSBP (sitting Systolic Blood Pressure) reduction compared to telmisartan + rosuvastatin (MD = −10.93 mmHg; 95% CI: −19.02 to −2.83; p = 0.008; I ² = 70%). sDBP (sitting Diastolic Blood Pressure) reductions were greater in the amlodipine group at 8 weeks (MD = −8.59 mmHg; 95% CI: −13.35 to −3.82; p = 0.0004; I ² = 58%). Conversely, LDL‐C reduction was favored by telmisartan + rosuvastatin, with significant effects observed at both 4 weeks (MD = 85.98 mg/dL) and 8 weeks (MD = 79.75 mg/dL). TEAE incidence did not differ significantly (RR = 1.23; 95% CI: 0.75–2.04; p = 0.41; I ² = 0%). Conclusion: Telmisartan + amlodipine demonstrates superior antihypertensive efficacy, while telmisartan + rosuvastatin more effectively lowers LDL‐C. Safety profiles are comparable. Findings support the selection of a regimen based on individualized therapeutic goals.Keywords
This publication has 13 references indexed in Scilit:
- Triple Therapy with Telmisartan, Amlodipine, and Rosuvastatin (TAR) Versus Telmisartan/Amlodipine (TA) and Telmisartan/Rosuvastatin (TR) Combinations in Hypertension and Dyslipidemia: A Systematic Review and Meta-analysisHigh Blood Pressure & Cardiovascular Prevention, 2024
- Effectiveness of Amlodipine in the Control of 24-Hour Blood Pressure in Mild-to-Moderate Essential Hypertension: A Prospective, Multicenter, Observational Real-World Study from IndiaCureus, 2023
- Efficacy and safety of co‐administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemiaThe Journal of Clinical Hypertension, 2020
- ACC/AHA Versus ESC/ESH on Hypertension GuidelinesJACC, 2019
- Efficacy and Tolerability of Telmisartan/Amlodipine and Rosuvastatin Coadministration in Hypertensive Patients with Hyperlipidemia: A Phase III, Multicenter, Randomized, Double-blind StudyClinical Therapeutics, 2019
- Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical TrialClinical Therapeutics, 2019
- Long-Term Tolerability and Efficacy of Single-Pill Combinations of Telmisartan 40–80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5–10 mg: Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 StudiesCurrent Therapeutic Research, 2012
- Synergism of Telmisartan and Amlodipine on Blood Pressure Reduction and Cardiorenal Protection in Hypertensive RatsJournal of Cardiovascular Pharmacology, 2011
- Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: A 24-week, randomized, open-label, prospective studyClinical Therapeutics, 2010
- Measuring inconsistency in meta-analysesBMJ, 2003